key: cord-0977332-608qk7bo
authors: Kerget, Buğra; Aksakal, Alperen; Kerget, Ferhan
title: Evaluation of the relationship between laboratory parameters and pulmonary function tests in COVID‐19 patients
date: 2021-04-27
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14237
sha: 8e30bf624016ee753be63adc2f57cbeb931134d9
doc_id: 977332
cord_uid: 608qk7bo

OBJECTIVE: The novel coronavirus SARS‐CoV‐2 (COVID‐19) rapidly escalated from its origin in an animal market in Wuhan, China in December 2019 to a global pandemic, and the lungs are the most frequently affected organ. The aim of this study was to investigate the relationship between pulmonary function test parameters and laboratory parameters in COVID‐19. METHOD: A total of 60 patients who were admitted to the chest diseases department and intensive care unit of our hospital and were diagnosed with COVID‐19 by real‐time PCR analysis of nasopharyngeal swabs were evaluated. Pulmonary function tests and laboratory parameters at admission and on day 7 of treatment were analysed. RESULTS: On day 7 of treatment, white blood cell count, CRP, and fibrinogen level were significantly lower than at admission (P = .002, 0.001, and 0.001, respectively), while forced expiratory volume in the first second (FEV(1)) and forced vital capacity (FVC) values were significantly higher compared with admitting values (P = .001 for both). Correlation analysis showed that the decrease in CRP from admission to day 7 of treatment correlated with the increase in FEV(1) (r = 0.616, P = .01) and FVC (r = 0.51, P = .01) during the same period. A decrease in the fibrinogen level was also correlated with an increase in FEV(1) (r = 0.345, P = .01) and FVC (r = 0.357, P = .01). CONCLUSION: Fibrinogen and CRP levels are easily accessible parameters that may help identify improvement or deterioration in pulmonary function in COVID‐19 patients during follow‐up and discharge while reducing the risk of transmission.

Results: On day 7 of treatment, white blood cell count, CRP, and fibrinogen level were significantly lower than at admission (P = .002, 0.001, and 0.001, respectively), while forced expiratory volume in the first second (FEV 1 ) and forced vital capacity (FVC) values were significantly higher compared with admitting values (P = .001 for both). Correlation analysis showed that the decrease in CRP from admission to day 7 of treatment correlated with the increase in FEV 1 (r = 0.616, P = .01) and FVC (r = 0.51, P = .01) during the same period. A decrease in the fibrinogen level was also correlated with an increase in FEV 1 (r = 0.345, P = .01) and FVC (r = 0.357, P = .01).

Conclusion: Fibrinogen and CRP levels are easily accessible parameters that may help identify improvement or deterioration in pulmonary function in COVID-19 patients during follow-up and discharge while reducing the risk of transmission.

It was also reported that pulmonary function tests performed at discharge revealed no significant difference in forced expiratory volume in the first second (FEV1) or forced vital capacity (FVC) values between COVID-19 patients with mild, moderate, and severe pneumonia, whereas diffusion capacity decreased in correlation with disease severity. Pulmonary function testing is often not recommended for patients with active COVID-19 infection in order to prevent excessive transmission. However, despite clinical improvement in this patient group, ongoing hypoxia and persistent radiological findings cause considerable difficulty in predicting the extent of improvement in pulmonary function.

While evaluating the laboratory parameters and radiological findings in patients with COVID-19

has become an easily accessible method, the inability to evaluate the pulmonary function infection in order to prevent excessive transmission. 6 However, despite clinical improvement in this patient group, ongoing hypoxia and persistent radiological findings cause considerable difficulty in predicting the extent of improvement in pulmonary function.

The aim of this study was to determine the relationship between pulmonary function tests and laboratory parameters for the demonstration of pulmonary dysfunction, which is an important problem for COVID-19 patients.

The study included patients who presented to the emergency department of Erzurum Regional Training and Research Hospital with complaints such as recent onset fever, cough, dyspnea, malaise, and sudden loss of taste and smell, and history of international travel or contact with a suspected COVID-19 patient in the last 14 days.

Patients (or their relatives) were informed in detail about the aim of the study and all participants provided informed consent forms before being included. Approval was obtained from the local ethics committee prior to study initiation. Starting at admission to the ward, the patients' hematological parameters, biochemical parameters including liver and kidney function tests, coagulation parameters, ferritin, D-dimer, troponin-I, and C-reactive protein (CRP) levels were evaluated daily.

Patients with any potential contraindications to pulmonary function testing (recent myocardial infarction, pulmonary embolism, cerebral aneurysm, active hemoptysis, pneumothorax, nausea/vomiting, recent thoracic, abdominal, or ocular surgery) were excluded before conducting the tests. In addition, patients who developed acute respiratory distress or macrophage activation syndrome associated with secondary bacterial infections during the 7-day follow-up were also excluded.

Pulmonary function tests were performed in a negative-pressure room by a technician wearing protective equipment to prevent capacities of patients in order to prevent contamination has become the most important problem in follow-up and discharge. Therefore, in our study in which easily accessible parameters were evaluated for guidance, we think that the combined decrease in CRP and fibrinogen levels may be related to increased pulmonary functional capacity.

transmission. The patients' age, height, and weight were measured and recorded. Before testing, patients were instructed to abstain from smoking (24 hours), alcohol (4 hours), strenuous exercise (30 minutes), and heavy meals (2 hours). Tests were performed with the patients lightly dressed. BTPS correction was performed according to room air and barometric pressure. The technician explained the desired manoeuvers to the patients and they performed three acceptable spirograms. Manoeuvers that met the ATS/ERS 2019 repeatability and acceptability criteria for pulmonary function tests were included. Expected values for the healthy population were also calculated on the spirometer in accordance with the criteria in this report. 7 All spirometry was performed by the same technician using a Plusmed MIR Spirolab III device.

Fever was defined as an axillary temperature of 37.3°C or above. 

Venous blood samples were obtained from all patients from an antecubital vein after at least 15 minutes of semisupine rest. Blood samples were collected into tubes containing ethylenediaminetetraacetic acid (EDTA) to prevent coagulation. Troponin-I levels were measured by chemiluminescent immunoassay using an Immulite 2500 device (Siemens Medical Solutions, Erlangen, Germany).

Data were analysed using IBM SPSS Statistics version 24.0 software (IBM Corp., Armonk, IL). Categorical variables were expressed as number and percentage; numerical variables were expressed as mean and standard deviation. Kolmogorov-Smirnov test was used to test whether the data were normally distributed. Repeated measures were compared using Friedman test and Wilcoxon test with Bonferroni correction for non-normally distributed numerical data.

Chi-square analysis was used to compare the percentages of patients whose FEV 1 and FVC values were lower than the expected value. Pearson correlation analysis was used to assess the relationship between changes in laboratory parameters and changes in pulmonary function tests. Results with P value <0.05 were considered statistically significant.

The mean age of the patients was 51.4 ± 18.2 years. Forty-two (70%) of the patients were men and 18 (30%) were women. The mean ages of the male and female patients were 55.1 ± 12.5 years and 50.1 ± 10.4 years, respectively (P = .04). The mean height and weight of the patients were 168.8 ± 9.1 cm and 82.3 ± 11.4 kg, respectively. Three of the patients had previously known coronary artery disease, five had diabetes mellitus, and one had asthma.

sults at admission and on day 7 of treatment are shown in Table 1 . Correlation analysis showed that the patients' change in CRP level from day 1 to day 7 (Δ 1-7 ) was correlated with the changes in FEV 1 and FVC from day 7 to day 1 (Δ 7-1 ) (r = 0.616, P = .01; r = 0.510, P = .01, respectively) ( Figure 2) . Similarly, Δ 1-7 fibrinogen was correlated with Δ 7-1 FEV 1 and FCV (r = 0.345, P = .01; r = 0.357, P = .01, respectively) ( Figure 3 ).

Amongst the laboratory parameters, CRP was found to be correlated with fibrinogen (r = 0.609, P P = .01) and ferritin (r = 0.308, P = .017).

Our study showed that COVID-19 patients' CRP, ferritin, and fi- ity that was correlated with disease severity. However, a striking aspect of the study was that the diffusing capacity of the lung F I G U R E 2 Correlation analysis between change in CRP level from day 1 to day 7 (Δ 1-7 ) and changes in FEV 1 and FVC from day 7 to day 1 (Δ 7-1 )

Correlation analysis between change in fibrinogen level from day 1 to day 7 (Δ 1-7 ) and changes in FEV 1 and FVC from day 7 to day 1 (Δ 7-1 )

for carbon monoxide (DLCO) decreased more than the diffusing capacity divided by alveolar volume (DLCO/VA), suggesting that the impairment of the diffusion membrane was a more important issue than low lung volume. 6 It was also observed that levels of D-dimer and acute phase reactants such as CRP, ferritin, and fibrinogen were elevated in

and that these parameters may be associated with morbidity and mortality. 15 Amongst these parameters, levels of CRP, fibrinogen, and ferritin levels were found to be high and inversely correlated with FEV 1 and FVC levels. [16] [17] [18] These acute phase reactants are elevated in most inflammatory diseases, and studies evaluating the relationship with parenchymal fibrosis in interstitial lung diseases have demonstrated increases in correlation with the extent of parenchymal fibrosis, highlighting their potential usefulness in follow-up. 19, 20 In the present study, we observed that the restrictive pattern ini- suggests that this parameter may be useful in evaluating progression to parenchymal fibrosis in this disease, which is characterised by pathologies also observed in interstitial lung diseases, such as hyaline membrane formation and alveolar septal fibrous proliferation.

The most important limitation of our study was the inability to evaluate diffusion capacities and total lung capacities when evaluating the aetiology of the restrictive pathology observed in pulmonary function tests. However, this was a result of the fact that only portable pulmonary function testing equipment could be placed in the negative pressure room established to minimise the chance of transmission.

In conclusion, although the assessment of laboratory parameters and radiological findings has become a convenient method for evaluating COVID-19 patients, the inability to evaluate patients' pulmonary function because of risk prevention measures has become the biggest problem in follow-up and discharge. In this study examined the guiding potential of some of these easily obtained parameters, we observed that decline in both CRP and fibrinogen levels may be associated with improved pulmonary functional capacity.

All authors disclosure no Conflict of Interest.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

A comprehensive review of COVID-19 characteristics

Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19?

Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome

Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and metaanalysis

Correlation between pneumonia severity and pulmonary complications in Middle East respiratory syndrome

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

Standardization of spirometry 2019 update. An official American thoracic Society and European respiratory Society technical statement

Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

The longterm impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome

Macrophage activation syndrome and COVID-19

Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge

Prognosis of COVID-19: Changes in laboratory parameters

Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study

Association of serum ferritin levels with smoking and lung function in the Korean adult population: analysis of the fourth and fifth Korean National Health and Nutrition Examination Survey

Relationship between plasma fibrinogen levels and pulmonary function in the Japanese population: the Takahata study

Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis

Serum analysis of coagulation factors in IPF and NSIP

Evaluation of the relationship between laboratory parameters and pulmonary function tests in COVID-19 patients